Innoviva (INVA) Net Margin (2011 - 2026)
Innoviva's (INVA) quarterly Net Margin came in at 190.41% in Q1 2026, up 24298.0% YoY from N/an in Q1 2025, and up 112.09% on a QoQ basis from 1575.3% in Q4 2025.
Innoviva (INVA) Net Margin (2011 - 2026) Analysis & Trends
Innoviva (INVA) has 16 years of Net Margin data on file, last reported at 190.41% in Q1 2026.
- Quarterly Net Margin rose 24298.0% year-over-year to 190.41% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 68.58% (up 12910.0% YoY) and the FY2025 annual result came in at 79.47%, up 7294.0% from the prior year.
- Net Margin climbed to 190.41% in Q1 2026, from 1575.3% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 1887.66% in Q1 2023 to a low of 16046.48% in Q4 2024.
- A 5-year average of 900.53% and a median of 36.07% in 2025 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2024 — Net Margin plunged 1538038 bps — and 2025, when it soared 1447118 bps.
- Tracing INVA's Net Margin over 5 years: stood at 1513.13% in 2022, then jumped by 56 bps to 666.1% in 2023, then plunged by 2309 bps to 16046.48% in 2024, then soared by 90 bps to 1575.3% in 2025, then surged by 112 bps to 190.41% in 2026.
- The last three Net Margin figures came in at 190.41% (Q1 2026), 1575.3% (Q4 2025), and 36.07% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 30.33% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.90% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 30.98% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 12.74% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -3.12% |
| 10 | Innoviva | 1.54 Bn | 968.79 Mn | 90.62 Mn | -69.75% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -69.75% |
| Mar 31, 2026 | 190.41% |
| Dec 31, 2025 | -1,575.30% |
| Sep 30, 2025 | 36.07% |
| Jun 30, 2025 | 63.51% |
| Mar 31, 2025 | -52.56% |
| Dec 31, 2024 | -16,046.48% |
| Sep 30, 2024 | 1.16% |
| Jun 30, 2024 | -34.72% |
| Mar 31, 2024 | 1,464.47% |
| Dec 31, 2023 | -666.10% |
| Sep 30, 2023 | 52.62% |
| Jun 30, 2023 | 45.28% |
| Mar 31, 2023 | 1,887.66% |
| Dec 31, 2022 | -1,513.13% |
| Sep 30, 2022 | 106.29% |
| Jun 30, 2022 | 22.86% |
| Mar 31, 2022 | 708.90% |
| Dec 31, 2021 | -4,537.82% |
| Sep 30, 2021 | 89.91% |